CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates
January 24, 2013 09:33 ET
|
Biodel Inc.
DANBURY, Conn., Jan. 24, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier today by Biodel Inc. (Nasdaq:BIOD), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The...
Biodel Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates
January 24, 2013 06:00 ET
|
Biodel Inc.
BIOD-238 and BIOD-250 demonstrate a pharmacokinetic profile superior to Humalog® with ultra-rapid absorption and rapid declines from peak concentration
BIOD-250 demonstrates injection...
Biodel Reports Fourth Quarter Fiscal Year 2012 Financial Results
December 18, 2012 06:00 ET
|
Biodel Inc.
DANBURY, Conn., Dec. 18, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2012.
Highlights of fourth fiscal...
Biodel to Report Fourth Quarter Fiscal Year 2012 Financial Results on December 18, 2012
December 14, 2012 07:00 ET
|
Biodel Inc.
DANBURY, Conn., Dec. 14, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its fourth quarter fiscal year 2012 financial results on December 18, 2012. Following the release of the...
FDA Grants Orphan Drug Designation to Biodel's Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Population
December 06, 2012 16:00 ET
|
Biodel Inc.
DANBURY, Conn., Dec. 6, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that the FDA has granted orphan drug designation for Biodel's 'glucagon' for the prevention of hypoglycemia...
Biodel Awarded NIH Grant to Develop Glucagon Formulations for Use in Artificial Pancreas
September 24, 2012 06:30 ET
|
Biodel Inc.
DANBURY, Conn., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has...
Biodel Reports Third Quarter Fiscal Year 2012 Financial Results
August 08, 2012 16:35 ET
|
Biodel Inc.
DANBURY, Conn., Aug. 8, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported financial results for the third fiscal quarter ended June 30, 2012.
Highlights since beginning of third...
Biodel to Report Third Quarter Fiscal Year 2012 Financial Results on August 8, 2012
August 01, 2012 06:00 ET
|
Biodel Inc.
DANBURY, Conn., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) will issue its third quarter fiscal year 2012 financial results on August 8, 2012. Following the release of the...
Biodel Announces Effectiveness of Reverse Stock Split
June 11, 2012 17:00 ET
|
Biodel Inc.
DANBURY, Conn., June 11, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that its Board of Directors has approved a reverse split of its common stock (the "Reverse Stock Split") at...
Committee for Orphan Medicinal Products Recommends Orphan Designation for Biodel's Stabilized Glucagon for the Treatment of Congenital Hyperinsulinism
January 20, 2012 07:00 ET
|
Biodel Inc.
DANBURY, Conn., Jan. 20, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has recommended...